Methods and devices for three-stage ventricular therapy

• US 8,874,208 B2
• Filed: 01/12/2012
• Issued: 10/28/2014
• Est. Priority Date: 12/11/2007
• Status: Active Grant

• Current Assignee: Washington University In St Louis
• Original Assignee: Washington University In St Louis
• Inventors: Efimov, Igor R., Li, Wenwen, Janardhan, Ajit
• Primary Examiner(s): Layno, Carl H
• Assistant Examiner(s): Morales, Jon Eric C
• Application Number:
  US13/349,527
• Publication Number:
  US 20120203297A1
• Time in Patent Office: 1,020 Days
• Field of Search: 607/5, 607/9, 607/14
• US Class Current: 607/5
• CPC Class Codes: A61N 1/3624 occurring in the atrium, i.e. atrial tachycardia
• CPC Class Codes: A61N 1/3906 characterised by the form of the shockwave
• CPC Class Codes: A61N 1/3918 characterised by shock pathway, e.g. by electrode configuration
• CPC Class Codes: A61N 1/395 for treating atrial fibrillation
• CPC Class Codes: A61N 1/3956 Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
• CPC Class Codes: A61N 1/3981 High voltage charging circuitry

Abstract

Methods and apparatus for a three-stage ventricular cardioversion and defibrillation therapy that treats ventricular tachycardia and fibrillation at low energy levels. An implantable therapy generator adapted to generate and selectively deliver a three-stage ventricular therapy and at least two leads operably each having at least one electrode adapted to be positioned proximate the ventricle of the patient. The device is programmed to deliver a three-stage therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of a ventricular arrhythmia. The three-stage therapy includes a first stage for unpinning of one or more singularities associated with the ventricular arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities associated delivered via the near-field configuration of the electrodes.

Claims

1. A ventricular arrhythmia treatment apparatus, comprising:

at least one electrode adapted to be implanted proximate a ventricle of a heart of a patient to deliver far field pulses;

at least one electrode adapted to implanted proximate the ventricle of the heart of the patient to deliver near field pulses and sense cardiac signals;

an implantable therapy generator adapted to be implanted in a patient and operably connected to the electrodes, including;

sensing circuitry that senses cardiac signals representative of ventricular activity;

detection circuitry operably connected to the sensing circuitry to evaluate the cardiac signals representative of ventricular activity to determine a ventricular cycle length and detect a ventricular arrhythmia based at least in part on the ventricular cycle length;

control circuitry operably connected to the sensing circuitry that, in response to the ventricular arrhythmia, controls generation and selective delivery of a three-stage ventricular therapy to the electrodes with each stage having an inter-stage delay of between 50 to 800 milliseconds; and

therapy circuitry operably connected to the electrodes and the control circuitry including;

at least one first stage charge storage circuit selectively coupled to the at least one far field electrode that selectively stores energy for a first stage of the three-stage ventricular therapy having at least two and not more than ten ventricular pulses of at least 2 volts and not more than 100 volts to unpin one or more singularities associated with the ventricular arrhythmia;

at least one second stage charge storage circuit selectively coupled to the at least one far field electrode that selectively stores a second stage of the three-stageventricular therapy having at least six and not more than ten far field pulses of less than a ventricular far-field excitation threshold with a pulse coupling interval of between 70-100% of the cycle length of the ventricular arrhythmia after the first stage therapy is applied, wherein the second stage prevents repinning of the one or more singularities associated with the ventricular arrhythmia that are unpinned by the first stage; and

at least one third stage charge delivery circuit selectively coupled to the near field electrode that selectively delivers a third stage of the three-stage cardioversion therapy having at least eight and not more than twelve near field pulses at a voltage substantially ranging from two to four times the diastolic pacing threshold, with a pulse coupling interval of between 70-100% of the cycle length of the ventricular arrhythmia, wherein the third stage extinguishes the one or more singularities associated with the ventricular arrhythmia that are unpinned by the first stage and prevented from repining by the second stage; and

a battery system operably coupled and providing power to the sensing circuitry, the detection circuitry, the control circuitry and the therapy circuitry.

2. The apparatus of claim 1, wherein the first stage pulses are monophasic pulses.

3. The apparatus of claim 1, wherein the first stage consists of three to five pulses.

4. The apparatus of claim 1, wherein the three-stage ventricular therapy delivers less than 0.1 J in total.

5. The apparatus of claim 1, wherein the third stage charge delivery circuit comprises a charge pump.

6. The apparatus of claim 1, wherein the third stage charge delivery circuit comprises at least one capacitor.

7. The apparatus of claim 1, wherein the first charge storage circuit includes at least one output capacitor configuration and a high voltage transformer electrically coupled to the battery system to charge the at least one output capacitor configuration.

8. The apparatus of claim 1, wherein the first charge storage circuit includes at least one output capacitor configuration and a charge pump electrically coupled to the battery system to charge the at least one output capacitor configuration.

9. The apparatus of claim 1, wherein the second charge storage circuit and third charge storage circuit include a single low voltage output capacitor configuration and switching circuitry between the single low voltage output capacitor configuration and the far field electrodes and the near field electrodes.

10. The apparatus of claim 1, wherein the control circuitry includes an H-bridge switching circuit operably connected to the electrodes to enable delivery of biphasic pulses.

11. The apparatus of claim 1, wherein the control circuitry controls delivery of the three-stage ventricular therapy to deliver in sequence one of the first stage, one of the second stage and one of the third stage.

12. The apparatus of claim 1, wherein the control circuitry controls delivery of the three-stage ventricular therapy to deliver in sequence one of the first stage, one of the second stage, one of the first stage, one of the second stage and one of the third stage.

13. The apparatus of claim 1, wherein the apparatus and the at least two leads include at least four far-field electrodes and the control circuitry is configured to selectively excite combinations of the far-field electrodes to create a plurality of different electric fields between different ones of the far-field electrodes to deliver a rotating set of electrical fields as a phased unpinning far-field therapy generated by the at least one first stage charge storage circuit and the at least one second stage charge storage circuit.

14. The apparatus of claim 1, wherein the control circuitry comprises a microprocessor programmed with a heuristic learning algorithm that dynamically modifies settings of the set of therapy parameters for the pulses of each stage in response to an effectiveness of the three-stage ventricular therapy.

15. A ventricular arrhythmia treatment apparatus, comprising:

an implantable therapy generator adapted to be implanted in a patient, including;

means for detecting a ventricular arrhythmia and determining a cycle length of the ventricular arrhythmia;

means for generating a three-stage ventricular therapy, including;

means for generating a first stage of the three-stage ventricular therapy having at least two and not more than ten monophasic ventricular pulses of at least 2 volts and not more than 100 volts for unpinning of one or more singularities associated with a ventricular arrhythmia;

means for generating a second stage of the three-stage atrial cardioversion therapy having at least six and not more than ten far field pulses of less than a ventricular far-field excitation threshold with a pulse coupling interval of between 70-100% of the cycle length of the ventricular arrhythmia for anti-repinning of the one or more singularities associated with the ventricular arrhythmia; and

means for generating a third stage of the three-stage cardioversion therapy having at least eight and not more than twelve near field pulses at a voltage substantially ranging from two to four times the diastolic pacing threshold with a pulse coupling interval of between 70-100% of the cycle length of the atrial arrhythmia for extinguishing of the one or more singularities associated with the ventricular arrhythmia; and

means for controlling delivery of the three-stage ventricular therapy in response to detection of the ventricular arrhythmia with each stage having an inter-stage delay of between 50 to 800 milliseconds; and

at least two leads adapted to be operably connected to the implantable therapy generator, each lead having at least one electrode adapted to be positioned proximate a ventricle of a heart of the patient through which the three-stage ventricular therapy is selectively delivered to the ventricle of the heart,

such that the means for generating the first stage and the means for generating the second stage are selectively coupled by the means for controlling delivery to a far-field configuration of the electrodes and the means for generating the third stage are selectively coupled by the means for controlling delivery to a near-field configuration of the electrodes.

16. The apparatus of claim 15, wherein the means for controlling delivery of the three-stage ventricular therapy delivers in sequence one of the first stage, one of the second stage and one of the third stage.

17. The apparatus of claim 15, wherein the means for controlling delivery of the three-stage ventricular therapy delivers in sequence one of the first stage, one of the second stage, one of the first stage, one of the second stage and one of the third stage.

18. The apparatus of claim 15, wherein the apparatus and the at least two leads include at least four far-field electrodes and the means for controlling delivery of the three-stage ventricular therapy is configured to selectively excite combinations of the far-field electrodes to create a plurality of different electric fields between different ones of the far-field electrodes to deliver a rotating set of electrical fields as a phased unpinning far-field therapy generated by the means for generating the first stage and the means for generating the second stage.

19. The apparatus of claim 15, wherein the means for controlling delivery further comprises a heuristic learning algorithm that dynamically modifies settings of the set of therapy parameters for the pulses of each stage in response to an effectiveness of the three-stage ventricular therapy.

20. The apparatus of claim 15, wherein the means for generating the three-stage ventricular therapy includes a battery system and the means for generating the first stage includes at least one output capacitor configuration and a high voltage transformer electrically coupled to the battery system to charge the at least one output capacitor configuration.

21. The apparatus of claim 15, wherein the means for generating the three-stage ventricular therapy includes a battery system and the means for generating the first stage includes at least one output capacitor configuration and a charge pump electrically coupled to the battery system to charge the at least one output capacitor configuration.

22. The apparatus of claim 21, wherein the means for generating the first stage includes a plurality of output capacitor configurations, one for each biphasic ventricular pulse, and the charge pump alternatively trickle charges each of the plurality of output capacitor configurations.

23. The apparatus of claim 15, wherein the at least two leads include a first lead having at least one far-field electrode and a second lead having at least one near-field electrode, and wherein the implantable pulse generator includes at least a portion of a housing of the implantable pulse generator that serves as a far-field electrode.

24. A method of treating ventricular arrhythmias comprising:

(a) causing a ventricular arrhythmia treatment device to be manufactured and made available to a user, ventricular arrhythmia treatment device including an implantable therapy generator adapted to generate and selectively deliver a three-stage ventricular therapy and at least two leads operably connected to the implantable therapy generator, each lead having at least one electrode adapted to be positioned proximate the ventricle of a heart of the patient;

(b) causing a ventricular arrhythmia treatment device to be manufactured and made available to a user;

providing instructions for implanting the ventricular arrhythmia treatment device in a patient during a surgical procedure;

(c) causing a ventricular arrhythmia treatment device to be manufactured and made available to a user;

providing instructions for configuring the ventricular arrhythmia treatment device at a time after completion of the surgical procedure, including instructions for programming the ventricular arrhythmia treatment device with a set of therapy parameters for delivering a three- stage ventricular therapy to a patient via both a far-field configuration and a near-field configuration of the electrodes upon detection of a ventricular arrhythmia by the ventricular arrhythmia treatment device, wherein the three-stage ventricular therapy includes;

a first stage of the three-stage ventricular therapy having at least two and not more than ten ventricular pulses of at least 2 volts and not more than 100 volts for unpinning of one or more singularities associated with a ventricular arrhythmia;

a second stage of the three-stage ventricular cardioversion therapy having at least six and not more than ten far field pulses of less than a ventricular far-field excitation threshold with a pulse coupling interval of 70-100% of the cycle length of the ventricular arrhythmia for anti-repinning of the one or more singularities associated with the ventricular arrhythmia; and

a

third stage of the three-stage cardioversion therapy having at least eight and not more than twelve near field pulses at a voltage substantially ranging from two to four times the diastolic pacing threshold with a pulse coupling interval of between 70-100% of the cycle length of the ventricular arrhythmia for extinguishing of the one or more singularities associated with the ventricular arrhythmia, and wherein the three-stage ventricular therapy is delivered in response to detection of the ventricular arrhythmia with each stage having an inter-stage delay of between 50 to 800 milliseconds.